Mankind Pharma announced a net profit of Rs 477 crore for the March quarter of FY24, marking a significant 62.3% increase from Rs 294 crore recorded in the previous year.
The Delhi-based pharmaceutical company also reported a notable 18.9% growth in revenue, reaching Rs 2,441 crore compared to Rs 2,052 crore in the corresponding period last year.
In terms of operating performance, EBITDA increased to Rs 591 crore from Rs 417 crore in the same period last fiscal, with an EBITDA margin of 24.2% compared to 20.3% previously.
